product summary
Loading...
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
CD279 (PD-1) Monoclonal Antibody (eBioJ105 (J105)), eBioscience
catalog :
14-2799-37
quantity :
2 mg
price :
US 1474
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
eBioJ105 (J105)
reactivity :
human, mouse, rhesus macaque
application :
immunohistochemistry, immunoprecipitation, flow cytometry, immunohistochemistry - frozen section
more info or order :
Invitrogen product webpage
citations: 37
Published Application/Species/Sample/DilutionReference
  • flow cytometry; human; 1:25; loading ...; fig 1f
Stebegg M, Bignon A, Hill D, Silva Cayetano A, Krueger C, Vanderleyden I, et al. Rejuvenating conventional dendritic cells and T follicular helper cell formation after vaccination. elife. 2020;9: pubmed publisher
  • flow cytometry; mouse; fig 6c
  • flow cytometry; human; fig 1b
Lynn R, Weber E, Sotillo E, Gennert D, Xu P, Good Z, et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature. 2019;576:293-300 pubmed publisher
Lai C, Tseng P, Chen C, Satria R, Wang Y, Lin C. Different Induction of PD-L1 (CD274) and PD-1 (CD279) Expression in THP-1-Differentiated Types 1 and 2 Macrophages. J Inflamm Res. 2021;14:5241-5249 pubmed publisher
Nelde A, Maringer Y, Bilich T, Salih H, Roerden M, Heitmann J, et al. Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia. Front Immunol. 2021;12:705974 pubmed publisher
Rouers A, Chng M, Lee B, Rajapakse M, Kaur K, Toh Y, et al. Immune cell phenotypes associated with disease severity and long-term neutralizing antibody titers after natural dengue virus infection. Cell Rep Med. 2021;2:100278 pubmed publisher
Singh Y, Trautwein C, Fendel R, Krickeberg N, Berezhnoy G, Bissinger R, et al. SARS-CoV-2 infection paralyzes cytotoxic and metabolic functions of the immune cells. Heliyon. 2021;7:e07147 pubmed publisher
Junker F, Gulati P, Wessels U, Seeber S, Stubenrauch K, Codarri Deak L, et al. A human receptor occupancy assay to measure anti-PD-1 binding in patients with prior anti-PD-1. Cytometry A. 2021;99:832-843 pubmed publisher
Roberts A, Bentley L, Tang T, Stewart F, Pallini C, Juvvanapudi J, et al. Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation. Sci Rep. 2021;11:4030 pubmed publisher
Bailur J, McCachren S, Pendleton K, Vasquez J, Lim H, Duffy A, et al. Risk-associated alterations in marrow T cells in pediatric leukemia. JCI Insight. 2020;5: pubmed publisher
Bauman J, Ohr J, Gooding W, Ferris R, Duvvuri U, Kim S, et al. Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer. Cancers (Basel). 2020;12: pubmed publisher
Wang Z, Zhao M, Yin J, Liu L, Hu L, Huang Y, et al. E4BP4-mediated inhibition of T follicular helper cell differentiation is compromised in autoimmune diseases. J Clin Invest. 2020;130:3717-3733 pubmed publisher
Kim J, Kim S, Shin E, Jung J, Choi H, Jun K. Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer. Oncol Lett. 2019;18:2661-2669 pubmed publisher
Brodska B, Otevrelova P, Salek C, Fuchs O, Gasova Z, Kuzelova K. High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations. Int J Mol Sci. 2019;20: pubmed publisher
Hill D, Pierson W, Bolland D, Mkindi C, Carr E, Wang J, et al. The adjuvant GLA-SE promotes human Tfh cell expansion and emergence of public TCRβ clonotypes. J Exp Med. 2019;: pubmed publisher
Belarif L, Mary C, Jacquemont L, Mai H, Danger R, Hervouet J, et al. IL-7 receptor blockade blunts antigen-specific memory T cell responses and chronic inflammation in primates. Nat Commun. 2018;9:4483 pubmed publisher
Watson A, Dai H, Diaz Perez J, Killeen M, Mathers A, Thomson A. mTORC2 deficiency in cutaneous dendritic cells potentiates CD8+ effector T cell responses and accelerates skin graft rejection. Am J Transplant. 2019;19:646-661 pubmed publisher
Nawaz F, Góes L, Ray J, Olowojesiku R, Sajani A, Ansari A, et al. MAdCAM costimulation through Integrin-α4β7 promotes HIV replication. Mucosal Immunol. 2018;11:1342-1351 pubmed publisher
Lee S, Adriani G, Ceccarello E, Pavesi A, Tan A, Bertoletti A, et al. Characterizing the Role of Monocytes in T Cell Cancer Immunotherapy Using a 3D Microfluidic Model. Front Immunol. 2018;9:416 pubmed publisher
Dunham J, van Driel N, Eggen B, Paul C, t Hart B, Laman J, et al. Analysis of the cross-talk of Epstein-Barr virus-infected B cells with T cells in the marmoset. Clin Transl Immunology. 2017;6:e127 pubmed publisher
Sumatoh H, Teng K, Cheng Y, Newell E. Optimization of mass cytometry sample cryopreservation after staining. Cytometry A. 2017;91:48-61 pubmed publisher
Davies L, Heldring N, Kadri N, Le Blanc K. Mesenchymal Stromal Cell Secretion of Programmed Death-1 Ligands Regulates T Cell Mediated Immunosuppression. Stem Cells. 2017;35:766-776 pubmed publisher
Jensen K, Dela Peña Ponce M, Piatak M, Shoemaker R, Oswald K, Jacobs W, et al. Balancing Trained Immunity with Persistent Immune Activation and the Risk of Simian Immunodeficiency Virus Infection in Infant Macaques Vaccinated with Attenuated Mycobacterium tuberculosis or Mycobacterium bovis BCG Vaccine. Clin Vaccine Immunol. 2017;24: pubmed publisher
Garcia Bates T, Kim E, Concha Benavente F, Trivedi S, Mailliard R, Gambotto A, et al. Enhanced Cytotoxic CD8 T Cell Priming Using Dendritic Cell-Expressing Human Papillomavirus-16 E6/E7-p16INK4 Fusion Protein with Sequenced Anti-Programmed Death-1. J Immunol. 2016;196:2870-8 pubmed publisher
Dunham J, Lee L, van Driel N, Laman J, Ni I, Zhai W, et al. Blockade of CD127 Exerts a Dichotomous Clinical Effect in Marmoset Experimental Autoimmune Encephalomyelitis. J Neuroimmune Pharmacol. 2016;11:73-83 pubmed publisher
Das R, Verma R, Sznol M, Boddupalli C, Gettinger S, Kluger H, et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol. 2015;194:950-9 pubmed publisher
Thaventhiran T, Alhumeed N, Yeang H, Sethu S, Downey J, Alghanem A, et al. Failure to upregulate cell surface PD-1 is associated with dysregulated stimulation of T cells by TGN1412-like CD28 superagonist. MAbs. 2014;6:1290-9 pubmed publisher
Moncunill G, Dobano C, McElrath M, De Rosa S. OMIP-025: evaluation of human T- and NK-cell responses including memory and follicular helper phenotype by intracellular cytokine staining. Cytometry A. 2015;87:289-92 pubmed publisher
Lee C, Fulcher D, Whittle B, Chand R, Fewings N, Field M, et al. Autosomal-dominant B-cell deficiency with alopecia due to a mutation in NFKB2 that results in nonprocessable p100. Blood. 2014;124:2964-72 pubmed publisher
Kenway Lynch C, Das A, Lackner A, Pahar B. Cytokine/Chemokine responses in activated CD4+ and CD8+ T cells isolated from peripheral blood, bone marrow, and axillary lymph nodes during acute simian immunodeficiency virus infection. J Virol. 2014;88:9442-57 pubmed publisher
Khammari A, Knol A, Nguyen J, Bossard C, Denis M, Pandolfino M, et al. Adoptive TIL transfer in the adjuvant setting for melanoma: long-term patient survival. J Immunol Res. 2014;2014:186212 pubmed publisher
Kap Y, van Driel N, Laman J, Tak P, t Hart B. CD20+ B cell depletion alters T cell homing. J Immunol. 2014;192:4242-53 pubmed publisher
Van Rompay K, Hunter Z, Jayashankar K, Peabody J, Montefiori D, LaBranche C, et al. A vaccine against CCR5 protects a subset of macaques upon intravaginal challenge with simian immunodeficiency virus SIVmac251. J Virol. 2014;88:2011-24 pubmed publisher
Knol A, Nguyen J, Pandolfino M, Quereux G, Brocard A, Peuvrel L, et al. Tissue biomarkers in melanoma patients treated with TIL. PLoS ONE. 2012;7:e48729 pubmed publisher
Shaw J, Hunt P, Critchfield J, McConnell D, Garcia J, Pollard R, et al. Short communication: HIV+ viremic slow progressors maintain low regulatory T cell numbers in rectal mucosa but exhibit high T cell activation. AIDS Res Hum Retroviruses. 2013;29:172-7 pubmed publisher
Bandyopadhyay G, Bankey P, Miller Graziano C. Trauma patients' elevated tumor necrosis related apoptosis inducing ligand (TRAIL) contributes to increased T cell apoptosis. Clin Immunol. 2012;145:44-54 pubmed publisher
Van Rompay K, Trott K, Jayashankar K, Geng Y, LaBranche C, Johnson J, et al. Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal. Retrovirology. 2012;9:57 pubmed publisher
Ghebeh H, Barhoush E, Tulbah A, Elkum N, Al Tweigeri T, Dermime S. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer. 2008;8:57 pubmed publisher
product information
Product Type :
Antibody
Product Name :
CD279 (PD-1) Monoclonal Antibody (eBioJ105 (J105)), eBioscience
Catalog # :
14-2799-37
Quantity :
2 mg
Price :
US 1474
Clonality :
Monoclonal
Purity :
Affinity chromatography
Host :
Mouse
Reactivity :
Human, Rhesus Monkey
Applications :
Flow Cytometry: 1 µg/test, Immunohistochemistry (Frozen): Assay-Dependent, Immunoprecipitation: Assay-Dependent
Species :
Human, Rhesus Monkey
Clone :
eBioJ105 (J105)
Isotype :
IgG1, kappa
Storage :
4° C
Description :
Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases. Despite its predicted molecular weight, PD-1 often migrates at higher molecular weight in SDS-PAGE.
Format :
Liquid
Applications w/Dilutions :
Flow Cytometry: 1 µg/test, Immunohistochemistry (Frozen): Assay-Dependent, Immunoprecipitation: Assay-Dependent
Aliases :
CD279; EGK_05005; hPD1; hPD-1; hPD-l; hSLE1; Ly101; mPD-1; PD1; PD-1; Pdc1; Pdcd1; programmed cell death 1; programmed cell death 1 protein; programmed cell death protein 1; programmed cell death protein 1-like; programmed death 1; Protein PD1; protein PD-1; sCD279; SLEB2; soluble CD279; systemic lupus erythematosus susceptibility 2
more info or order :
Invitrogen product webpage
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com
800-678-5599
headquarters: USA